Lantern Pharma Inc (LTRN)

$3.62 -0.11 (-2.95%)
Market Cap 40.23M
Revenue (ttm) 0.00
Net Income (ttm) -20.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 15,100
Avg Vol 42,326
Day's Range N/A - N/A
Shares Out 10.79M
Stochastic %K 68%
Beta 1.63
Analysts Strong Sell
Price Target $25.50

Latest News on LTRN

Lantern Pharma Inc. (LTRN) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 8:35 PM EDT - 4 weeks ago

Lantern Pharma Inc. (LTRN) Q4 2024 Earnings Call Transcript

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

Mar 27, 2025, 4:01 PM EDT - 4 weeks ago

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET

Mar 20, 2025, 8:00 AM EDT - 5 weeks ago

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

Feb 19, 2025, 8:00 AM EST - 2 months ago

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

Jan 27, 2025, 7:55 AM EST - 3 months ago

Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Dec 9, 2024, 8:15 AM EST - 4 months ago

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

Dec 3, 2024, 8:00 AM EST - 5 months ago

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

Nov 26, 2024, 8:45 AM EST - 5 months ago

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Nov 19, 2024, 8:00 AM EST - 5 months ago

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 7:23 PM EST - 5 months ago

Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

Nov 7, 2024, 4:05 PM EST - 6 months ago

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

Nov 5, 2024, 8:00 AM EST - 6 months ago

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

Oct 31, 2024, 8:00 AM EDT - 6 months ago

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024

Oct 23, 2024, 8:45 AM EDT - 6 months ago

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024

Lantern Pharma to Host & Participate in Two Public Webinars During October

Oct 21, 2024, 8:00 AM EDT - 6 months ago

Lantern Pharma to Host & Participate in Two Public Webinars During October

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA

Oct 15, 2024, 9:07 AM EDT - 6 months ago

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers

Sep 23, 2024, 8:00 AM EDT - 7 months ago

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers

Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 4:01 AM EDT - 9 months ago

Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates

Aug 8, 2024, 4:01 PM EDT - 9 months ago

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates

Lantern Pharma Highlights Promising Preclinical Results of LP-184's Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024

Aug 7, 2024, 9:31 AM EDT - 9 months ago

Lantern Pharma Highlights Promising Preclinical Results of LP-184's Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

Aug 5, 2024, 8:00 AM EDT - 9 months ago

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET

Aug 1, 2024, 8:00 AM EDT - 9 months ago

Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

Jul 10, 2024, 8:30 AM EDT - 10 months ago

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284

Jun 12, 2024, 7:30 AM EDT - 11 months ago

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights

May 9, 2024, 4:02 PM EDT - 1 year ago

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

May 6, 2024, 3:00 AM EDT - 1 year ago

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET

May 2, 2024, 7:30 AM EDT - 1 year ago

Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET

Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

Apr 24, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

Apr 22, 2024, 8:12 AM EDT - 1 year ago

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript

Mar 18, 2024, 11:14 PM EDT - 1 year ago

Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

Mar 18, 2024, 4:02 PM EDT - 1 year ago

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET

Mar 11, 2024, 7:30 AM EDT - 1 year ago

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET

Lantern To Participate in H.C Wainwright & Co.'s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

Mar 5, 2024, 8:01 AM EST - 1 year ago

Lantern To Participate in H.C Wainwright & Co.'s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines

Mar 4, 2024, 8:01 AM EST - 1 year ago

Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers

Feb 15, 2024, 8:01 AM EST - 1 year ago

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer

Jan 17, 2024, 7:30 AM EST - 1 year ago

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)

Nov 30, 2023, 8:00 AM EST - 1 year ago

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)

Lantern Pharma Inc. (LTRN) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 5:28 AM EST - 1 year ago

Lantern Pharma Inc. (LTRN) Q3 2023 Earnings Call Transcript

Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights

Nov 8, 2023, 4:01 PM EST - 1 year ago

Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights

Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET

Nov 1, 2023, 8:00 AM EDT - 1 year ago

Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET

Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET

Oct 10, 2023, 8:00 AM EDT - 1 year ago

Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET

Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma

Oct 3, 2023, 8:00 AM EDT - 1 year ago

Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma

Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors

Sep 25, 2023, 8:30 AM EDT - 1 year ago

Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors

Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin's Lymphomas

Sep 18, 2023, 9:00 AM EDT - 1 year ago

Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin's Lymphomas

Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin's Lymphomas at the Society of Hematologic Oncology Annual Meeting

Aug 31, 2023, 8:00 AM EDT - 1 year ago

Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin's Lymphomas at the Society of Hematologic Oncology Annual Meeting

Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors

Aug 28, 2023, 8:00 AM EDT - 1 year ago

Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors

Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT

Aug 14, 2023, 8:30 AM EDT - 1 year ago

Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT

Lantern Pharma Inc. (LTRN) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 8:25 PM EDT - 1 year ago

Lantern Pharma Inc. (LTRN) Q2 2023 Earnings Call Transcript

Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights

Aug 9, 2023, 4:01 PM EDT - 1 year ago

Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights